Release date: 2015-05-21
Although it has long been reported that replacing the blood of the elderly with the blood of young people can play an anti-aging role. It was not until 2013 that researchers from Harvard University first linked a molecule, GDF11, circulating in the blood to this effect. They released this important discovery in a 2014 Science paper. In another Science paper published in the same period, the researchers also confirmed that GDF11 can promote neurogenesis and angiogenesis in the brains of aged mice.
The current theory of why blood in young mice can rejuvenate the muscles of aging mice has been questioned. An analysis published in the May 19 issue of Cell Metabolism began to investigate the mechanism by which GDF11 works in muscle, but the opposite result was obtained.
The researchers first revealed that Harvard did not specifically detect GDF11; some methods used in the past did not specifically target GDF11, but instead tested myostatin, which is very similar to GDF11, which is known to inhibit muscle growth.
The new study, led by David Glass of the Novartis Institute for Biomedical Research, uses some tests to more accurately detect GDF11 in animals and human blood, and found some signs that GDF11 increases with age, clearly confirming that GDF11 does not Decreased as young grows. They also confirmed that regular injections of purified GDF11 into mice resulted in worsening muscle repair, similar to some of the effects seen in the elderly.
Se-Jin Lee, a growth/differentiation factor expert and molecular biologist at Johns Hopkins University (not involved in the study) said: "This is a meticulous study that will definitely trigger the role of GDF11 in aging muscles. Intense discussion."
Lee said: "I believe that these findings clearly question the validity of GDF11 in the previous paper. Obviously, it is necessary to analyze these inconsistencies in another study, especially considering that the pharmaceutical industry is Great efforts have been made to target myostatin signaling pathways to treat muscle wasting."
The researchers found that giving GDF11 to older animals at the doses used in the past did not promote regeneration as previously claimed. When young animals were treated with GDF11, regeneration worsened. The authors developed a test to specifically detect GDF11 levels and suggested that for humans, people with high levels of GDF11 may be eligible for drug therapy that blocks GDF11 activity.
Caroline Brun and Michael A. Rudnicki of the Ottawa Hospital Research Institute said: "Obviously, like the spring of youth in mythology, GDF11 is not a long-awaited factor that can restore youth. New research findings indicate that it also needs to be in the heart and brain. Re-testing the activity of GDF11's 'returning to the old child' - because of the basic premise of these two Science papers: GDF11 decreases with age and contradicts new papers."
Source: Biopass
The United States Food and Drug Administration (FDA) has published the Dietary Supplement Health and Education Act (DSHEA), which provides for dietary supplements. A product (other than tobacco) intended to supplement the diet may contain one or more of the following dietary ingredients: A vitamin, a mineral, an herb (herbal) or other plant, an amino acid, a food component used to increase the total daily intake to supplement the diet, or a concentrate, metabolite, component, extract or combination of the above ingredients, etc. It also includes approved new drugs, vitamins or biologics that have been marketed as dietary supplements or food products before they are approved, issued or licensed. The DSHEA defines dietary supplements as their composition and labeling requirements: the product form may be pill, capsule, tablet or liquid; The product shall not be used as a substitute for ordinary foods or as an exclusive dietary item. The product shall be labeled as a "dietary supplement".
Dietary Supplements,Arachidonic Acid Powder,Kava Root Powder,Kava Root Extract Powder
Xi'an Double H Health Technology Co., Ltd , https://www.xahnhcj.com